SPOP and prostate carcinoma: Increasing evidence indicates that prostate cancer-derived SPOP mutants function in a dominant-negative manner31–33, which is consistent with the findings from biochemical and structural studies showing that the SPOP protein can form a dimer or oligomer via its BTB domain and BACK domain34,35.